What the Xifaxan TV commercial - You Know the Symptoms is about.
The Xifaxan TV spot, titled "You Know the Symptoms," is a commercial advertisement that promotes a medication called Xifaxan. The ad is focused on raising awareness about Irritable Bowel Syndrome with diarrhea (IBS-D) and encourages viewers to talk to their doctors about Xifaxan as a potential treatment option.
The ad begins by showing a woman who is struggling with the symptoms of IBS-D, including chronic diarrhea and abdominal pain. The woman appears to be miserable and is shown staying close to a bathroom due to her symptoms. The commercial then highlights the fact that millions of people suffer from IBS-D and that the symptoms can significantly impact one's quality of life.
The ad then emphasizes the importance of seeking treatment for IBS-D and encourages viewers to talk to their doctors about Xifaxan. The Xifaxan medication is marketed as a prescription option that can help alleviate the symptoms of IBS-D by targeting the underlying cause of the issue, which is an imbalance of bacteria in the gut. The commercial claims that Xifaxan has been shown to provide relief for abdominal pain, diarrhea, and bloating associated with IBS-D.
Throughout the advertisement, the Xifaxan brand is presented in a professional and trustworthy manner. The ad focuses on the medication's positive effects and is intended to motivate viewers to take action by seeking medical advice and treatment. Overall, the Xifaxan TV spot succeeds in delivering a clear and concise message about IBS-D and the importance of treating its symptoms with the help of Xifaxan.
Xifaxan TV commercial - You Know the Symptoms produced for
Xifaxan
was first shown on television on October 4, 2015.
Frequently Asked Questions about xifaxan tv spot, 'you know the symptoms'
In clinical trials, more patients taking XIFAXAN vs. placebo for 2 weeks had relief of IBS-D symptoms for 10 weeks following treatment. Median duration of symptom relief was 10 weeks (range of 6 to 24 weeks). You can be retreated up to 2 times if symptoms return.
It is used to treat traveler's diarrhea and irritable bowel syndrome with diarrhea. It is also used to prevent hepatic encephalopathy, a brain disorder that can occur due to severe liver disease. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
There's no cure for IBS, but medications along with dietary and lifestyle changes can help you prevent flare-ups.
For Irritable Bowel Syndrome with Diarrhea(IBS-D), the suggested dose of rifaximin is 400 mg three times or 550 mg twice daily for two weeks. IBS-D may require intermittent rifaximin treatment. Typically, 200 mg three times daily is given for three days in traveler's diarrhea.
Rifaximin is a gastrointestinal-selective antibiotic with a broad spectrum of antimicrobial activity, an excellent safety profile, minimal drug interactions, and negligible impact on the intestinal microbiome.
Long-term treatment
For traveler's diarrhea and IBS-D, Xifaxan isn't meant to be taken long term. If your doctor prescribes Xifaxan for these conditions, you'll typically take the drug for 3–14 days.
IBS does not shorten the lifespan of affected individuals or lead to major life-threatening complications in most patients, and most serious symptoms can be avoided through a controlled diet and avoiding stressful situations, as stress and anxiety are known to cause IBS flare-ups.
IBS Clinical Trials “Pipeline” Boom in 2023
Promising pipeline therapies include Olorinab, Blautix, ORP-101, Rifamycin controlled-release, and several other treatments.
Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy.
Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice during rifaximin treatment due to the risk of increased rifaximin exposure and adverse reactions. Rifaximin is a P-gp substrate and grapefruit juice is a P-gp inhibitor.
Although rifaximin exerts antibacterial effects against a wide range of Gram-positive and Gram-negative bacteria in vitro, our study found that rifaximin administration did not affect the stability of the gut microbiota, and that the antibacterial effect of rifaximin in the intestine was not significant.
Most studies used doses around 600 mg twice daily in treatment periods up to 6 months and reported that rifaximin is effective and safe to prevent hepatic encephalopathy.